Revenues from new (and safer) HIV meds, including Descovy, Genvoya, and Odefsey, are soothing a drop-off in this biopharma company’s hepatitis C drug sales.
News about Gilead Sciences
Some counterintuitive lessons.
The charity has become a political headache for Hillary Clinton.
And why the world needs even more affordable drugs.
Pfizer has agreed to pay a little more than $80 per share for Medivation, a source said.
Brand reputation isn't necessarily tied to cash giving, however.